Pharmaceutical - Pharmaceutical, Pacira Pharmaceuticals

Filter

Popular Filters

Ph III data shows Pacira’ Exparel good as femoral nerve block in knee arthroplasty

06-04-2014

US drugmaker Pacira Pharmaceuticals has released additional Phase III data supporting the efficacy and…

ExparelNeurologicalPacira PharmaceuticalsPharmaceuticalResearch

US Senator seeks answers from drugmakers on providing required discounts

27-09-2013

US Senator Charles Grassley has written to two drug companies on behalf of an Iowa hospital that is not…

CSL BehringExparelHematologyKcentraNeurologicalNorth AmericaPacira PharmaceuticalsPharmaceuticalPoliticsPricing

Exparel Ph III trial in intercostal nerve block fails to meet primary endpoint

02-08-2013

USA-based Pacira Pharmaceuticals (Nasdaq: PCRX) has reported results from its second pivotal, Phase III…

ExparelNeurologicalPacira PharmaceuticalsPharmaceuticalResearch

EMA recommendations to deal with sterility concerns for DepoCyte

27-08-2012

The European Medicines Agency last Friday agreed a number of precautionary measures to deal with manufacturing…

DepoCyteEuropeMundipharmaOncologyPacira PharmaceuticalsPharmaceuticalRegulationSigma Tau

Pacira and SkyePharma leap as FDA approves painkiller Exparel

02-11-2011

New Jersey, USA-based Pacira Pharmaceuticals (Nasdaq: PCRX) and UK drugmaker SkyePharma (LSE: SKP) both…

ExparelFinancialNeurologicalNorth AmericaPacira PharmaceuticalsPharmaceuticalRegulationSkyepharma

Back to top